Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
September 30, 2026
September 30, 2026
CAMBRIDGE, Massachusetts, Sept. 30 -- The Massachusetts Institute of Technology posted the following news:
* * *
Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
*
About 25 percent of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tum . . .
* * *
Lung cancers can use two different mechanisms to evade KRAS-inhibiting drugs
*
About 25 percent of lung adenocarcinomas have mutations of the gene KRAS, which drives uncontrolled cell growth. In recent years, the FDA has approved two KRAS inhibitors to treat patients with KRAS mutations. While these drugs can work well initially, tum . . .